No­vo nabs over a third of di­a­betes mar­ket, a year ahead of sched­ule

No­vo Nordisk’s GLP-1 drugs may have been the cen­ter of at­ten­tion dur­ing its first-quar­ter earn­ings call, but the com­pa­ny’s broad­er di­a­betes port­fo­lio beat its tar­get …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER